Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Case Rep ; 5(10): 1628-1633, 2017 10.
Article in English | MEDLINE | ID: mdl-29026560

ABSTRACT

Systemic treatment of Medullary thyroid carcinoma (MTC) is currently limited to the use of a tyrosine kinase inhibitor. Cytotoxic chemotherapy is not routinely recommended in the earlier lines of treatment due to the lack of efficacy. We describe a patient with locally advanced MTC who had an uncommon response to cisplatin and etoposide.

2.
Mol Clin Oncol ; 4(5): 779-782, 2016 May.
Article in English | MEDLINE | ID: mdl-27123278

ABSTRACT

Polymorphous low-grade adenocarcinoma is an uncommon malignant tumor derived from the terminal duct cells of the salivary glands. The present study described a rare case of polymorphous low-grade adenocarcinoma, T2N0M0 stage 2, in a 65-year-old man, who presented with a sore throat and painful dysphagia. Computed tomography revealed an infiltrative heterogenous enhancing mass involving the left aryepiglottic fold. He underwent a tumor removal with frozen section for evaluating the surgical margin. Subsequent supraglottic laryngectomy was performed. Polymorphous low-grade adenocarcinoma was diagnosed histologically, characterized by cytologic uniformly, morphologic diversity and an infiltrative growth pattern. Epiglottic cartilaginous invasion by the tumor is demonstrated. Clinical, radiological, endoscopic and pathological features with briefly reviewed relevant literatures are discussed. This is the first reported description in the literature, to the best of our knowledge, of an epiglottic polymorphous low-grade adenocarcinoma receiving successful supraglottic laryngectomy with 7 year disease free survival.

3.
J Med Assoc Thai ; 97(6): 655-61, 2014 Jun.
Article in English | MEDLINE | ID: mdl-25137883

ABSTRACT

OBJECTIVE: To identify the treatment outcome of glioblastoma multiforme (GBM) in Ramathibodi Hospital from overall survival rate and related prognostic factors. MATERIAL AND METHOD: Medical records of patients with histological diagnosis of GBM treated at Radiation Oncology Division, Radiology Department, Ramathibodi Hospital between 2000 and 2010 were reviewed and available data extracted for evaluation of treatment outcome. RESULTS: There were 47 patients with mean age at diagnosis of 51.9 years (range from 18 to 82 years). Surgery (partial 76.6%, total 12.8%, and biopsy 10.6%) followed by postoperative radiotherapy (mean dose 52 gray) was the treatment of choice with or without concurrent and adjuvant Temozolomide (TMZ). With median follow-up time of 0.9 years, the median survival of the patients was 2.1 years (95% CI 1.08-7.36), whereas one and two-year overall survival rates were 78.0% and 57.8%, respectively. In univariate analysis, persistent neurological deficit after surgery and presenting symptom of visual disturbance were identified to lower overall survival while multivariate analysis, younger age, and higher radiation dose were identified as favorable prognostic factors to improve overall survival. Re-surgery or re-irradiation in some selected cases of recurrent or progressive disease was considered as a choice for palliative treatment. CONCLUSION: Proper management of GBM patient was surgical removal and postoperative radiotherapy with or without chemotherapy. Proper palliative treatment modality was considered in selected cases of recurrent or progressive disease.


Subject(s)
Brain Neoplasms/radiotherapy , Glioblastoma/radiotherapy , Adolescent , Adult , Aged , Aged, 80 and over , Brain Neoplasms/mortality , Combined Modality Therapy , Female , Glioblastoma/mortality , Humans , Male , Middle Aged , Retrospective Studies , Treatment Outcome
4.
J Med Assoc Thai ; 96(5): 603-13, 2013 May.
Article in English | MEDLINE | ID: mdl-23745317

ABSTRACT

OBJECTIVE: Evaluate the effectiveness of radiotherapy plan and physical parameters including local tumor response and clinical outcome of lung metastasis in patients who received CyberKnife treatment at Ramathibodi Hospital. MATERIAL AND METHOD: Six cases with twenty lesions of lung metastasis patients were evaluated for tumor response after having received CyberKnife treatment. The prescribed radiation dose was calculated approximately to biological equivalent dose (BED) around 60 to 100 gray (Gyz). The response of each lesion to treatment was evaluated from roentgenographic study during follow-up period along with adverse event, status of patients, and disease. RESULTS: At the third month after treatment, roentgenographic partial response (PR, 50% decrease in size) was demonstrated in eight lesions and stable disease (SD, unchanged size) in eight lesions with no complete response (CR, disappearance of tumor) detected. Progressive disease (PD, 25% increase in size) of six treated lesions was detected during the follow-up period. At the time of report, two patients were alive and still received palliative chemotherapy, two patients died from uncontrolled progressive metastases and failed palliative chemotherapy, and two patients lost follow-up after progressive metastases with unknown surviving status. No severe adverse event was observed. The treatment planning parameters demonstrated borderline of radiation dose homogeneity, and conformality coverage of the target volume. CONCLUSION: This preliminary report aimed to provide the idea of choosing the appropriate lung metastasis patient to receive CyberKnife treatment that must strictly clarify the real clinical benefit of each selected case to achieve the best outcome from this special treatment procedure.


Subject(s)
Antineoplastic Agents/therapeutic use , Lung Neoplasms , Neoplasms , Palliative Care/methods , Radiosurgery , Combined Modality Therapy/methods , Disease Progression , Dose-Response Relationship, Radiation , Female , Humans , Lung/pathology , Lung/surgery , Lung Neoplasms/diagnosis , Lung Neoplasms/secondary , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasms/classification , Neoplasms/pathology , Radiosurgery/adverse effects , Radiosurgery/instrumentation , Radiosurgery/methods , Tomography, X-Ray Computed , Treatment Outcome
5.
J Med Assoc Thai ; 95(10): 1335-43, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23193750

ABSTRACT

OBJECTIVE: Provide the effectiveness of treatment protocol, radiotherapy plan, technique, and early clinical results of inoperable primary non-small cell lung cancer (NSCLC) in patients who received CyberKnife treatment at Ramathibodi Hospital. MATERIAL AND METHOD: Six cases of inoperable primary NSCLC patients were evaluated for tumor response after having received CyberKnife treatment. The prescribed radiation dose was 45 gray (Gy) in three consecutive fractions for peripherally located tumor and 50 Gy in five fractions within two weeks for centrally located tumor (biological equivalent dose, BED, 112.5 Gy 10, and 100 Gy 10, respectively). The response to treatment was evaluated from roentgenographic study during follow-up period along with clinical outcome and adverse event. RESULTS: Overall response after the treatment was demonstrated in five cases with roentgenographic complete response (CR, disappearance of tumor) and partial response (PR, 50% decrease in size) in two and three cases, respectively without any severe adverse event. The treatment planning parameters demonstrated the effectiveness of radiation dose homogeneity and conformity coverage of the target volume. CONCLUSION: This preliminary report has provided the effectiveness of treatment plan and local tumor controlled without severe adverse event for primary inoperable NSCLC patients receiving CyberKnife treatment.


Subject(s)
Carcinoma, Non-Small-Cell Lung/surgery , Lung Neoplasms/surgery , Radiosurgery , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Cohort Studies , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Thailand , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...